LERK-3 (Ephrin-A3/EFNA3) Recombinant Protein: Mechanisms, Biomedical Applications, and Translational Innovations

1. Concept

LERK-3, also known as Ephrin-A3 (EFNA3), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein belonging to the Ephrin ligand family. Its recombinant form is primarily produced using the HEK293 expression system, with a C-terminal His-tag for efficient purification. Structurally, LERK-3 features four core functional modules: a signal peptide facilitating membrane localization, a highly conserved ~20 kDa Ephrin domain mediating specific binding to Eph receptors, a cysteine-rich GPI anchoring domain ensuring stable membrane attachment, and a flexible linker region enabling conformational adaptability for different Eph receptor subtypes. Glycosylation modifications at key N-linked sites (e.g., Asn-32, Asn-65) regulate its stability and receptor binding affinity. LERK-3 exerts biological effects through "bidirectional signaling" upon interaction with Eph receptors (predominantly EPHA subtypes), playing critical roles in neurodevelopment, angiogenesis, and disease pathogenesis, while holding therapeutic potential for tumors, spinal cord injuries, and autoimmune disorders.

2. Research Frontiers

Recent advances in LERK-3 research have unlocked key insights into its structure, signaling, and translational potential. Cryo-electron microscopy (cryo-EM) has resolved the 3D structure of LERK-3, revealing a groove-shaped receptor-binding interface that complements the ligand-binding domain of Eph receptors (e.g., EPHA8), explaining its high-affinity interaction. Glycosylation has been identified as a pivotal regulatory factor, not only enhancing protein stability but also fine-tuning receptor binding specificity.

In signaling biology, studies have delineated LERK-3’s bidirectional signaling mechanisms: forward signaling drives cytoskeletal remodeling via Rho GTPase, while reverse signaling recruits adaptor proteins (e.g., PDZ domain-containing proteins) to activate Src kinase or PI3K/AKT pathways. Technological breakthroughs address current challenges: 2024 research in Nature Biotechnology reports high-affinity anti-LERK-3 nanobodies (KD=0.8 nM) engineered via phage display, extending in vivo half-life from 2.3 hours to 72 hours and improving tissue penetration. CRISPR-Cas9-based tissue-specific knockout models enable precise functional analysis, overcoming Ephrin family functional redundancy. Emerging trends focus on developing second-generation recombinant proteins with tissue targeting and long-acting stability through directed evolution and non-canonical amino acid insertion.

3. Research Significance

LERK-3 research holds profound significance in basic biology and clinical medicine. As a key regulator of neurodevelopment, it guides neural crest cell migration and spinal cord neuronal network formation, providing insights into developmental disorders. Its dose-dependent role in angiogenesis (proliferation at low concentrations, apoptosis at high concentrations) makes it a target for treating pathological angiogenesis-related diseases.

Therapeutically, LERK-3 offers promising avenues for multiple disorders: soluble recombinant LERK-3 (sEFNA3) reduces melanoma lung metastasis by competitively blocking Eph receptors; hydrogel-encapsulated LERK-3 improves spinal cord injury motor function recovery by 42%; and it inhibits Th17 cell differentiation to alleviate autoimmune diseases (57% reduction in rheumatoid arthritis joint inflammation). By unraveling LERK-3’s signaling networks, researchers gain insights into disease mechanisms (e.g., tumor metastasis, autoimmune pathogenesis), accelerating the development of precision therapies.

4. Related Mechanisms, Research Methods, and Product Applications

Mechanisms

LERK-3 mediates its diverse functions through Eph receptor-dependent bidirectional signaling:

• Forward Signaling: Binding to Eph receptors activates downstream cascades, including Rho GTPase-mediated cytoskeletal remodeling, regulating neuronal axon guidance and vascular endothelial cell migration.
• Reverse Signaling: Despite lacking a transmembrane domain, LERK-3 recruits cytoplasmic adaptor proteins via its intracellular segment, activating Src kinase or PI3K/AKT pathways to modulate cell adhesion and survival.
• Dose-Dependent Regulation: Exerts opposing effects on angiogenesis (proliferation vs. apoptosis) and disease progression based on concentration, forming the basis for therapeutic dosage optimization.

Research Methods and Product Applications

ANT BIO PTE. LTD. offers high-quality antibodies (Starter sub-brand) and recombinant proteins (UA sub-brand) to support LERK-3 research, enabling mechanistic studies, therapeutic development, and functional validation:

• Antibody Applications:
• His tag (C-terminal) Recombinant Rabbit mAb (FITC Conjugate) facilitates the detection and purification of recombinant LERK-3 (which features a C-terminal His-tag), supporting protein expression validation and binding assay optimization.
• Islet1 and CD25/IL-2Rα Recombinant Rabbit mAbs enable the study of LERK-3’s role in neurodevelopment and autoimmune regulation, respectively, by profiling relevant cell populations and signaling pathways.
• MTBR-Tau243 Recombinant Rabbit mAbs support investigations into LERK-3’s potential role in neurodegenerative diseases, complementing its known neurodevelopmental functions.
• Recombinant Protein Applications:
• Siglec-3 (R69G) His Tag Protein (Human, HEK293-expressed) serves as a reference standard for glycosylation studies, aiding in the analysis of LERK-3’s glycosylation-dependent function.
• Functional Research Support: These reagents are compatible with key techniques such as immunoprecipitation, Western blotting, and cell-based assays, enabling the elucidation of LERK-3’s signaling mechanisms, receptor interactions, and therapeutic potential in disease models.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with innovative, high-quality reagents and solutions to accelerate scientific discovery and clinical translation. We specialize in providing antibodies, recombinant proteins, ELISA kits, and general life science reagents through three dedicated sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Backed by advanced development platforms—including recombinant monoclonal antibody platforms, multi-system recombinant protein expression (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA Platform, and PTM Pan-Modification Antibody Platform—we adhere to stringent international certifications (EU 98/79/EC, ISO9001, ISO13485). Our mission is to be a trusted partner for researchers worldwide, delivering reliable products and tailored services that drive breakthroughs in developmental biology, oncology, regenerative medicine, and autoimmune disease research.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.